Contineum Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTNM research report →
Range $17 – $23
Price Chart
About the company
Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
- CEO
- Carmine N. Stengone
- IPO
- 2024
- Employees
- 51
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on CTNM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $306.87M
- P/E
- -5.11
- PEG
- -0.21
- P/S
- 0.00
- P/B
- 1.41
- EV/EBITDA
- -3.48
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -25.48%
- ROIC
- -28.77%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-68,059,000
- Net Income
- $-59,978,000-41.9%
- EPS
- $-2.17-33.1%
- OCF Growth
- -68.4%
- FCF Growth
- -66.5%
- 52W High
- $17.79
- 52W Low
- $6.72
- 50D MA
- $10.66
- 200D MA
- $13.27
- Beta
- 0.75
- RSI (14)
- 39
- Avg Volume
- 776.03K
No earnings-call transcripts are available for CTNM yet.
- Free Float
- 85.1%
- Shares Outstanding
- 35.35M
- Float Shares
- 30.10M
of shares held by institutions
105 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Montanova Capital, LLC | 2.84M | 0 |
| Jupiter Topco LLC | 2.73M | ▲ 2.73M |
| Janus Henderson Group Ltd. | 2.73M | ▲ 285.86K |
| Fmr LLC | 2.61M | ▲ 1.57M |
| Blackrock, Inc. | 2.22M | ▲ 159.12K |
| Johnson & Johnson | 1.98M | 0 |
| Franklin Templeton Inc | 1.70M | ▼ 134.68K |
| Balyasny Asset Management L.P. | 1.52M | ▼ 162.84K |
| Vanguard Capital Management LLC | 1.36M | ▲ 41.04K |
| Versant Venture Management, LLC | 1.29M | ▲ 750.00K |
| Vanguard Group Inc | 1.27M | ▲ 306.63K |
| Perceptive Advisors LLC | 1.26M | 0 |
Held by 138 ETFs
Biggest fund positions in CTNM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 8, 26 | Stengone Carmine N. | other | 2,500 |
| Sep 8, 26 | Stengone Carmine N. | other | 2,500 |
| Sep 8, 26 | Stengone Carmine N. | sell | 2,500 |
| Aug 3, 26 | Stengone Carmine N. | other | 2,500 |
| Aug 3, 26 | Stengone Carmine N. | other | 2,500 |
| Aug 3, 26 | Stengone Carmine N. | sell | 2,500 |
| Jul 8, 26 | Lorrain Daniel S. | other | 1,015 |
| Jul 9, 26 | Lorrain Daniel S. | other | 25 |
| Jul 9, 26 | Lorrain Daniel S. | sell | 25 |
| Jul 8, 26 | Lorrain Daniel S. | other | 1,015 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CTNM coverage
Recent articles, reports, and earnings notes.
No research on CTNM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CTNM report →Qureight's Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial
businesswire.com · Nov 9
Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
businesswire.com · Nov 3
All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy
zacks.com · Oct 12
Why Is Contineum Therapeutics Stock Falling Monday?
benzinga.com · Oct 12
48,108 Contineum Therapeutics, Inc. $CTNM Shares Sold by Squarepoint Ops LLC
defenseworld.net · Sep 25
Contineum Therapeutics (NASDAQ:CTNM) Trading Down 9.9% After Analyst Downgrade
defenseworld.net · Sep 16
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
benzinga.com · Sep 15
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
businesswire.com · Sep 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.